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In a 2007 radiologic follow up, two meningiomas are found (left cerebellum and right pterional región) which progressively grew
in the following years. Reason for which he was again referred to our service in February 2011 for evaluation of treatment with RT
and he was administered 54Gy at a isodose of 95% (5×200 cGy). Treatment ends July 2011. Current status Presents radiological
control of the lesions with residual neurological stability that had initially.
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Three year old, female patient. PPH: No medical or surgical background of relevance. OH: On September 1979 this patient experi-
ments progressive impotence of the right leg. During studies performed at the traumatology department in “Hospital San Rafael”
in Madrid a lithic image on the right iliac blade is discovered, an a biopsy compatible with Ewing Sarcoma is found. Another study
is performed on 04/14/1980, a bone scan, in which an intense pathological formation of activity at right iliac level is observed, and
an even higher formation is noted at the left proximal femur which could correspond to the overload caused by the adaptation
of an antalgic position. The rest of complementary studies were unremarkable. A combined chemotherapy treatment with CVA
(VCR, ADM, CPX)×2 cycles is decided upon with concurrent radiotherapy at a acurative dosage. Treatment is performed RT-2D
on right hemipelvis. 45Gy dose with subsequent overprinting on tumor volume reaching a total dose of 65Gy. Fractionation
5×200 cGy. Ending the day 20 – May-1980. Well tolerated.
Evolution. At a follow up in 1985, the tumor was under clinical control but there were some after effects to the radiotherapy
which included limited abduction and rotation of the lower right extremity and a 3.5 cm shortening of such limb that required
treatment with ALZA. And also some ﬁbrosis in the gluteal muscles where the radiation was given. In 2006 this patient was
intervened to a myomectomy with a diagnosis of uterine leiomyoma. Currently she remains symptom free (ILE 384).
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Introduction. Ewing sarcoma is a rare tumor with an annual incidence of 2–3 cases/million habitants. It is a neuroendocrine tumor
of adolescent males more frequently located in the pelvis or long bones. Biopsy is required for diagnosis. Bad prognosis factors
are the location in the axial skeleton, adult mean age, the large tumor size and metastatic debut. It is a highly aggressive tumor
with the ability to metastasize to the lung. They are to chemotherapy and radiotherapy sensitive. The 5-year survival is 30% if
debut with metastasis.
Case. 11 year old boy who complains of pain in pelvis. In MR imaging presents 14 cm bone and soft tissue mass which inﬁltrate the
obturador muscle, contact with bladder and displace the bowel without metastases at the diagnoses. Received chemotherapy,
autologous hematopoietic stem cell (bone marrow biopsy was negative) and radical radiotherapy to the left ilium with 55.8Gy.
As toxicity he presented radiodermitis grade II with complete response. At 3 years of diagnosis presented pulmonary bilateral
progression resistant to chemotherapy. He didn’t receive radiotherapy due to previous toxicity so he was operated (pulmonary
nodules exeresis) and he received a new line chemotherapy. Currently the patient is stable with no evidence of recurrence.
Conclusions.We report a patientwith poor prognosis for high initial local aggressiveness and unresectable diseasewith pulmonary
metastases who receipt a multidisciplinary treatment with AHSC+QT+RT. The patient is stable without sings of local recurrence
or distant 5 years after diagnosis.
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Introduction. The gliosarcoma is the most common tumor within gliomesenquimales rare tumors. Usually settle in the temporal
lobe and affects more men.
Case report. Patient follow-up since 2005 for left mesial temporal lesion of 1.5 cm which debuted with partial seizures. Following
MRI until June 2008 when referring to morphological change observed and is derived neurosurgery treatment. Complete
tumor excision was performed and subsequent treatment with external beam radiotherapy (44–60Gy+Boost, fractionation
2Gy/day) + concomitant temozolomide (75mg/m2/day) treatment ending on 03/06/2009, subsequently received 6 cycles of
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temozolomide in monotherapy 150mg/m2/D1–5 (1st cycle) and 200mg/m2/D1–5 ending in December 2009. Currently has
headaches that disappear with analgesia, with no signs of recurrence in serial MRI. Progression-free interval > 3 years.
Discussion. First described in 1895, is a variant of glioblastoma multiforme (2–8%) with a glial and a sarcomatous component.
With peak incidence between 50-70 years, male: female ratio of 1.4:1 and most common in the temporal lobe. The sarcomatous
component can metastasize (15-30%, more than the glioblastoma multiforme) more frequently to spinal cord, lung, bone and
lymph nodes and surrounding structures. The glial usually corresponds to glioblastoma, although sometimes described oligo-
dendrogliomas or subependymomas. The survival ranges from 8 to 24 months. Rarely occur as multicentric tumors. Factors
affecting overall survival are age at presentation, extent of resection, adjuvant radiotherapy and race, has been that men have
more survival and tumor size also has an impact at this level.
Conclusions. It is a rare tumor with a worse prognosis than glioblastoma multiforme, where a good surgical and adjuvant therapy
with RTE+QT is a determining factor in overall survival.
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Granulocytic sarcoma (GS) is an uncommon extramedullary tumor composed of dense aggregates of immaturemyeloid precursor
cells, which is usually associated with acute or chronic myeloid leukemia. The tumor may also be a predecessor to acute myeloid
leukemia (AML). It may be found in any location throughout the body; however, intraoral occurrence is extremely rare. Radiation
therapy is often used in the treatment of chloromas, we reviewed one case to analyze treatment response, disease control and
toxicity associated with RT. Our patient is a 61 year old woman was diagnosed in 2007 of breast carcinoma which was treated with
chemotherapy: secondary of this treatment, the patient developed an AML in March 2010.PETHEMA protocol is included in 2007
and is administered LAM induction IDA-ARAC. Autotransplant performed in 2011. Few months ago, complained of pain in right
jaw so it is sampled with a diagnosis of mandibular granulocytic sarcoma, in the analyzed sample objective decline granulocytic
series and blast population (60%) and aberrant expression of CD7, so it was decided to administer RT dose of 30Gy in 15 fractions
with concomitant chemotherapy. Patients are most often referred for RT for chloromas at recurrence or progression although
radiation might have a role in other cases, a low dose of radiation (30Gy in 15 fx) can be applied with excellent disease control
and combinated modality therapy is warranted.
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The midline angiocentric lymphoma (also known as lethal midline granuloma) is a rare lymphoid neoplasm, with an often-
difﬁcult diagnosis due to the non-speciﬁc symptoms. This lymphoma is an aggressive Non-Hodgkin’s (NHL) type, which is
normally found in the upper respiratory tract (often in the nasal cavity), and has a bad prognosis, as the average survival rate is
between 12 and 18 months, without treatment. It is predominantly found in patients who are between 50 and 60 years old and
with a slight tendency towards males. Case report: At September 1995, Spanish male patient (59 years old) was referred to Oto-
laringology Department with fever, purulent rhinorrhea, headache, weight loss and nasal respiratory obstruction. Polypectomy
was performed at January of 1996; it was found histologically that the patient had a lethal midline granuloma. CT revealed a mass
encroaching on the right frontal sinus, maxillary sinus and nostril to nasopharynx. He received chemotherapy and radiotherapy
(40Gy on ethmoid and maxillary sinuses and 10Gy on nasals and ethmoid sinuses) treatments were successful and lesion had
disappeared. Currently, sixteen years later, our patient is still alive without any kind of symptoms.
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Introduction. The anaplasic astrocytoma (AA) is included as a grade III glioma in the OMS classiﬁcation. The patients with AA
have a median of survival of 17–24 months after the diagnosis. Inside the prognosis factors, it is included: age, mental state at
the diagnosis and the general state (PS). The standard treatment is based on surgery (maximum possible resection), followed by
postoperative radiotherapy (RT). The use of adjuvant chemotherapy (QT) is controversial in the AA. The amount of exeresis has
been linked with the increase of patients survival.
Case report. Male patient, of 55 years old, who after a traumatic brain injury with loss of consciousness is diagnosed by brain
MRI a deep temporal intra-axial expansive lesion with left lenticulocapsular caudal participation of about 4.5 cm in maximum
